B4 ((55, 12i?)dihydroxy-6, 14-cw,8, 10-frans-eicosatetraenoic acid, LTB4), a potent activator of polymorphonuclear leukocytes (PMNLs) is known to be an endogenous mediator of several inflammatory diseases such as psoriasis1* and ulcerative colitis2 The fermentation broth (15 liters) was filtered, and the filtrate was passed through a column of polymeric adsorbent (Diaion HP-20, Mitsubishi Chemical). The column was washed with water and the adsorbent was eluted with methanol. The eluate was concentrated under reduced pressure and the residue was partitioned between ethyl acetate and water. The ethyl acetate fraction was subjected to column chromatography on silica gel (Kieselgel 60, Merck). The columnwas washedwith chloroform and active compoundwas eluted with chloroformmethanol (20 : 1). After evaporation to dryness, the residue was applied to a reverse phase column (YMC-GEL ODS-A, Yamamura Chemical). The column was washed with 70%aqueous methanol Fig. 1 . Effect of WS6629 on LTB4-induced^-glucuronidase release in rabbit PMNLs.
frans-eicosatetraenoic acid, LTB4), a potent activator of polymorphonuclear leukocytes (PMNLs) is known to be an endogenous mediator of several inflammatory diseases such as psoriasis1* and ulcerative colitis2 The fermentation broth (15 liters) was filtered, and the filtrate was passed through a column of polymeric adsorbent (Diaion HP-20, Mitsubishi Chemical). The column was washed with water and the adsorbent was eluted with methanol. The eluate was concentrated under reduced pressure and the residue was partitioned between ethyl acetate and water. The ethyl acetate fraction was subjected to column chromatography on silica gel (Kieselgel 60, Merck). The columnwas washedwith chloroform and active compoundwas eluted with chloroformmethanol (20 : 1). After evaporation to dryness, the residue was applied to a reverse phase column (YMC-GEL ODS-A, Yamamura Chemical). The column was washed with 70%aqueous methanol PMNLsuspensions (5 x 106 cells/ml) were incubated with WS6629or vehicle for 5 minutes at 37°C. LTB4 (7 x 10~8 m) together with cytochalasin B (10~5 m) were then added and incubated for 5 minutes at 37°C. The amountof /?-glucuronidase released from the cells were quantitated. The results were expressed as percent of the enzyme release from WS6629-treated cells (means+SEM, n=3) when compared to the release from vehicle-treated cells. * P<0.05, ** P<0.01 and *** P<0.001. and the desired compound was eluted with 90% aqueous methanol. The eluate was concentrated to give 320mg of WS6629 as a crystalline form. The crystalline WS6629 exhibits mp 156~158°C and is optically active, [a]£5 -62.8°(c 1.0, EtOH). These physico-chemical properties and the IR spectrum data (data not shown) of WS6629are identical with the data from novobiocin reported by the Upjohn group5). *H and 13C NMRanalysis also supported the structure of WS6629to be I.
In the PMNL degranulation assay4), WS6629 significantly decreased the LTB4-induced PMNL Fig. 2 . Effect of WS6629 on 3H-LTB4 binding to PMNLmembranes.
The membrane suspension (from 2 x 106 cells) and value. WS6629 significantly inhibited AA-induced ear edema at a dose from O.lmg/ear whengiven topically (Table 1) . However, the inhibition did not 
